Zoetis (NYSE:ZTS) Stock Picked Up by Analysts at The Goldman Sachs Group

Stock analysts at The Goldman Sachs Group began coverage on shares of Zoetis (NYSE:ZTS) in a note issued to investors on Friday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $74.00 price target on the stock. The Goldman Sachs Group’s price target would indicate a potential downside of 6.69% from the stock’s current price.

Several other research analysts have also recently commented on ZTS. HSBC lowered their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. William Blair restated a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. UBS Group decreased their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research report on Tuesday, August 25th. Finally, Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Seven investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $99.14.

Zoetis Stock Performance

Shares of ZTS opened at $79.31 on Friday. Zoetis has a 1 year low of $68.77 and a 1 year high of $148.30. The stock has a market capitalization of $32.77 billion, a PE ratio of 13.07, a PEG ratio of 1.87 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock has a 50-day simple moving average of $74.03 and a 200-day simple moving average of $83.26.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the prior year, the firm earned $1.76 earnings per share. The business’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts predict that Zoetis will post 6.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zoetis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. State Street Corp boosted its holdings in shares of Zoetis by 1.8% in the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after buying an additional 343,322 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Zoetis by 7.3% in the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after buying an additional 327,313 shares in the last quarter. Deutsche Bank AG grew its position in shares of Zoetis by 5.8% in the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after buying an additional 319,709 shares during the last quarter. Finally, Swedbank AB grew its position in shares of Zoetis by 9.9% in the 1st quarter. Swedbank AB now owns 3,004,200 shares of the company’s stock valued at $355,126,000 after buying an additional 269,610 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.